Skye Bioscience Signs Collaboration and License Agreement with Halozyme
I'm PortAI, I can summarize articles.
Skye Bioscience Inc. has signed a Non-exclusive Collaboration and License Agreement with Halozyme, Inc. for the use of Halozyme’s ENHANZE® drug delivery technology. The agreement includes milestone and royalty payments, with Halozyme supplying clinical and commercial rHuPH20 bulk drug product. This collaboration aims to develop a subcutaneous formulation of nimacimab.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments